Study of safety and efficacy profile of systemic corticosteroids (prednisolone tablets) and isotretinoin tablets versus systemic corticosteroids (prednisolone tablets) alone in cutaneous lichen planus (violet colored itchy elevated lesions over body)

Not Applicable

Completed

• Conditions: Health Condition 1: null- Cutaneous lichen planus

• Registration Number: CTRI/2017/10/010292
• Lead Sponsor: Krishna Institute of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 60

Inclusion Criteria

A.Must give written consent before any treatment commenced.

B.Must be diagnosed to be suffering from cutaneous lichen planus either by clinical examination or histopathology if required.

C.Must have generalised lichen planus involving minimum 20% body surface area or cases of palmoplantar lichen planus

D.Must stop any other modality of treatment, two months prior to the inclusion in study.

E.Must be able and willing, in the view of investigator, to comply all study procedure.

Exclusion Criteria

A. Patient having only oral lichen planus, genital lichen planus, nail lichen planus, follicular lichen planus, actinic lichen planus, lichen planus pigmentosus, lichen planus pemphigoides,

B. Patient with hypersensitivity to drug or patient intolerant to the study medication.

C. Pregnant and lactating patient.

D. Patient with unrealistic expectations.

E. Not willing for regular follow up.

F. Patient with clinically significant cardiovascular, haematological, pancreatic, metabolic neurological or any other laboratory anomaly, which in the judgement of investigator, would interfere in participation in study or proper evaluation.

G. Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results.

H. Patient having history of tuberculosis or chest X-ray showing evidence of any infective pathology.

I. Immunocompromised patients

Study & Design

• Study Type: Interventional
• Study Design: Not specified